Name: Bayesian Designs for Phase I-Ii Clinical Trials (Chapman & Hall (en Inglés)
Price: 48460.00 CLP
Availability: InStock
Author: Ying Yuan; Hoang Q. Nguyen; Peter F. Thall
ISBN: 9781032242644

portada Bayesian Designs for Phase I-Ii Clinical Trials (Chapman & Hall (en Inglés)

Formato

Libro Físico

Editorial

Crc Pr Inc

Autor

Ying Yuan; Hoang Q. Nguyen; Peter F. Thall

Idioma

Inglés

N° páginas

324

Encuadernación

Tapa Blanda

ISBN13

9781032242644

N° edición

Bayesian Designs for Phase I-Ii Clinical Trials (Chapman & Hall (en Inglés)

Ying Yuan; Hoang Q. Nguyen; Peter F. Thall (Autor) · Crc Pr Inc · Tapa Blanda

Libro Nuevo

$ 48.460

$ 80.770

Ahorras: $ 32.310

40% descuento

Envío normal

Origen: Estados Unidos (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Miércoles 12 de Junio y el Miércoles 26 de Junio.

Lo recibirás en cualquier lugar de Chile entre 1 y 3 días hábiles luego del envío.

Reseña del libro "Bayesian Designs for Phase I-Ii Clinical Trials (Chapman & Hall (en Inglés)"

Reliably optimizing a new treatment in humans is a critical first step in clinical evaluation since choosing a suboptimal dose or schedule may lead to failure in later trials. At the same time, if promising preclinical results do not translate into a real treatment advance, it is important to determine this quickly and terminate the clinical evaluation process to avoid wasting resources. Bayesian Designs for Phase I-II Clinical Trials describes how phase I-II designs can serve as a bridge or protective barrier between preclinical studies and large confirmatory clinical trials. It illustrates many of the severe drawbacks with conventional methods used for early-phase clinical trials and presents numerous Bayesian designs for human clinical trials of new experimental treatment regimes.Written by research leaders from the University of Texas MD Anderson Cancer Center, this book shows how Bayesian designs for early-phase clinical trials can explore, refine, and optimize new experimental treatments. It emphasizes the importance of basing decisions on both efficacy and toxicity.